# EDGAR Filing Document

**Accession Number:** 0001835022
**File Stem:** 0000000000-25-008542
**Filing Date:** 2025-8
**Character Count:** 2181
**Document Hash:** 26b1119bb88069f89308a77d9cd9dc3d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008542.hdr.sgml**: 20250917

**ACCESSION NUMBER**: 0000000000-25-008542

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250813

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coya Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001835022
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289511

**BUSINESS ADDRESS:**
- **STREET 1:** 12645 MEMORIAL DR., SUITE F1 #305
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77024
- **BUSINESS PHONE:** 650.739.3939

**MAIL ADDRESS:**
- **STREET 1:** 12645 MEMORIAL DR., SUITE F1 #305
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77024
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-178531

## Text-Extract

```

                                                           August 13, 2025

Arun Swaminathan
Chief Executive Officer
Coya Therapeutics, Inc.
5850 San Felipe St., Suite 500
Houston, TX 77057

        Re: Coya Therapeutics, Inc.
            Registration Statement on Form S-3
            Filed August 12, 2025
            File No. 333-289511
Dear Arun Swaminathan:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Jessica Dickerson at 202-551-8013 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Daniel C. Porco, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._